ICRM
ACHN

Insight Capital Research & Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Insight Capital Research & Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-87,462
Closed -$662K – 153
2014
Q2 		$662K Buy
+87,462
New +$349K 0.15% 102

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Insight Capital Research & Management's ACHN Position: Q3 2014 in Review

Insight Capital Research & Management sold out of Achillion Pharmaceuticals (ACHN) in Q3 2014, closing a stake of 87,462 shares — an estimated $662K sold.

Insight Capital Research & Management first reported a position in ACHN in Q2 2014 and held it in 1 quarter. The position peaked at $662K in Q2 2014. 161 funds tracked by Wall St. Rank hold ACHN as of Q3 2014.

  • Insight Capital Research & Management reported no remaining Achillion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Insight Capital Research & Management sold 87,462 Achillion Pharmaceuticals shares in Q3 2014, an estimated $662K.
  • Insight Capital Research & Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Insight Capital Research & Management's Achillion Pharmaceuticals position peaked at $662K in Q2 2014.
  • 161 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2014.

Based on Insight Capital Research & Management's 13F filing for Q3 2014, filed 6 Nov 2014.